AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33687687
Drug: Repository Corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository Corticotropin Injection (RCI; Acthar) 80 U subcutaneously every other day through week 4, then twice weekly through week 24
Trial: 33687687
Drug: Repository Corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository Corticotropin Injection (RCI; Acthar)
Trial: 33688022
Drug: Galunisertib 150
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galunisertib 150 mg two times per day co-administered with durvalumab 1500 mg Q4W
Trial: 33688228
Drug: Orlistat (120mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120mg three times daily) and Phentermine (37.5mg once daily)
Trial: 33688228
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three times daily) and Phentermine (37.5mg once daily)
Trial: 33688834
Drug: Tri/tetracyclic antidepressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri/tetracyclic antidepressants + SGA
Trial: 33688834
Drug: Psychotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy alone (without medication)
Trial: 33691262
Drug: GLS-010 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS-010 at a dose of 240 mg Q2W
Trial: 33691262
Drug: GLS-010 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS-010 at doses of 1, 4, or 10 mg/kg Q2W; 240 mg Q3W or Q2W
Trial: 33691480
Drug: Evinacumab, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evinacumab, dosage and duration not specified
Trial: 33691765
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (thromboprophylactic doses of LMWH or UFH)
Trial: 33692132
Drug: siBcl2L12-SNAs (NU-0129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siBcl2L12-SNAs (NU-0129) administered intravenously at a dose corresponding to 1/50th of the no-observed-adverse-event level
Trial: 33692132
Drug: siBcl2L12-SNAs (NU-0129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siBcl2L12-SNAs (NU-0129) administered intravenously
Trial: 33692727
Drug: Communication skills
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Communication skills training for radiographers; details on dosage and duration not available
Trial: 33693009
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard oxygen therapy)
Trial: 33693776
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg gliclazide
Trial: 33693813
Drug: No Vitamin
RxNorm normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No Vitamin D supplements
Trial: 33693943
Drug: Anti-HIV antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-HIV antibodies
Trial: 33694257
Drug: Lenalidomide (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (starting dose 2 mg/kg/day on days 1-21 of each 28-day cycle for a maximum of 12 cycles)
Trial: 33704071
Drug: Bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine lactoferrin 150 mg
Trial: 33704071
Drug: Bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine lactoferrin 300 mg
Trial: 33705565
Drug: Oxytocin solution
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin solution
Trial: 33706339
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg orally followed by misoprostol 800 micrograms buccally
Trial: 33707233
Drug: Intratumoral tilsotolimod
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral tilsotolimod (8 mg) with systemic ipilimumab
Trial: 33708474
Drug: Inappropriate low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate low doses of NOACs
Trial: 33708484
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg monthly injections
Trial: 33708780
Drug: Low-dose decitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose decitabine (LD-DAC, 5 mg/m²)
Trial: 33708965
Drug: Docetaxel continuation
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel continuation maintenance (DCM) therapy
Trial: 33710399
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no atypical antipsychotic during pregnancy)
Trial: 33710523
Drug: First/second-generation EGFR-tyrosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First/second-generation EGFR-tyrosine kinase inhibitors (1G/2G EGFR-TKIs)
Trial: 33710523
Drug: Other systemic
RxNorm normalized name: Other systemic hemostatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other systemic treatments
Trial: 33710523
Drug: Subsequent systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent systemic treatment after progression on 1G/2G EGFR-TKIs
Trial: 33710976
Drug: Tedizolid phosphate
RxNorm normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tedizolid phosphate (3-6 mg/kg, single oral or intravenous dose)
Trial: 33711074
Drug: TAK-003 (tetravalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-003 (tetravalent live attenuated dengue vaccine)
Trial: 33711699
Drug: Granulocyte-Colony Stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-Colony Stimulating Factors (G-CSF)
Trial: 33712086
Drug: Dichloroacetate (DCA)
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloroacetate (DCA) 6.25 mg/kg oral capsules twice daily for 6 weeks, potentially increasing to 12.5 mg/kg twice daily for another 6 weeks if pain is not adequately controlled
Trial: 33712849
Drug: Venetoclax 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax 400 mg/day (3-day ramp up in cycle 1) plus azacitidine 75 mg/m2 on days 1-7 per 28-day cycle
Trial: 33713216
Drug: HLX07 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX07 at 50 mg
Trial: 33713216
Drug: HLX07 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX07 at 100 mg
Trial: 33713216
Drug: HLX07 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX07 at 200 mg
Trial: 33713216
Drug: HLX07 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX07 at 400 mg
Trial: 33713216
Drug: HLX07 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX07 at 600 mg
Trial: 33713216
Drug: HLX07 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX07 at 800 mg
Trial: 33713742
Drug: Cisplatin at
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin at 30 mg/m² with adjuvant radiation therapy
Trial: 33713742
Drug: Cisplatin at
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin at 10 mg/m²
Trial: 33715620
Drug: eGDR tertile
RxNorm normalized name: textiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGDR tertile T3 (≤ 4.14 mg/kg/min, highest IR)
Trial: 33715620
Drug: eGDR tertile
RxNorm normalized name: textiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGDR tertile T1 (≥ 5.35 mg/kg/min)
Trial: 33716499
Drug: Various anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various anesthetic agents
Trial: 33716499
Drug: Inhalational agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalational agents
Trial: 33716817
Drug: Pharmacological treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment, specific details not available.
Trial: 33716948
Drug: Arm-Hand Boost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm-Hand Boost Therapy during inpatient stroke rehabilitation
Trial: 33717057
Drug: BCMA-directed Chimeric
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCMA-directed Chimeric Antigen Receptor T cells (CART) therapy
Trial: 33718228
Drug: Therapeutic cancer
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic cancer vaccination with peptide CALRLong36, 15 vaccines administered
Trial: 33719441
Drug: GLPG1972/S201086, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1972/S201086, a potent and selective ADAMTS-5 inhibitor, dosage and duration not specified.
Trial: 33719441
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group not specified, but implied as untreated or standard treatment.
Trial: 33719721
Drug: PH FDC
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PH FDC SC (subcutaneous injection)
Trial: 33719728
Drug: Nonmotor experiences
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmotor experiences of daily living
Trial: 33720032
Drug: eVisits for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eVisits for sore throat (guideline-recommended antibiotics)
Trial: 33720032
Drug: eVisits for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eVisits for respiratory symptoms (guideline-recommended antibiotics)
Trial: 33720032
Drug: eVisits for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eVisits for dysuria (guideline-recommended antibiotics)
Trial: 33720336
Drug: Lisocabtagene maraleucel
RxNorm normalized name: Lisocabtagene Maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisocabtagene maraleucel (CAR T-cell therapy)
Trial: 33720337
Drug: Rituximab-based therapies
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab-based therapies (including R-Dox) with maintenance AZT/VGC or interferon
Trial: 33720337
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments administered at investigator discretion
Trial: 33720337
Drug: Concurrent diagnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent diagnosis of PEL
Trial: 33720424
Drug: pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab 200 mg every 3 weeks for 3 cycles
Trial: 33720749
Drug: Bundled Acupuncture
RxNorm normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bundled Acupuncture and Yoga Therapy
Trial: 33721289
Drug: Anticholinergic Drug
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic Drug Scale (ADS)
Trial: 33721837
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) 1000 IU single dose
Trial: 33722701
Drug: Chemotherapy including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chemotherapy including steroids (dexamethasone)
Trial: 33722855
Drug: OBI-999 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBI-999 (a novel antibody-drug conjugate targeting Globo H)
Trial: 33723220
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg over 40 min)
Trial: 33723260
Drug: Personalized whole-tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC) combined with bevacizumab (Bev), cyclophosphamide (Cy), acetylsalicylic acid (ASA), and low-dose interleukin (IL)-2
Trial: 33723507
Drug: SOC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC plus ivermectin 100 mcg/kg
Trial: 33723507
Drug: SOC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC plus ivermectin 200 mcg/kg
Trial: 33723507
Drug: SOC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC plus ivermectin 400 mcg/kg
Trial: 33723724
Drug: TAS-117 (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-117 (16 mg daily for GI cancers; 24 mg on a 4 days on/3 days off schedule for non-GI cancers)
Trial: 33724632
Drug: BAY 94-9027
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 94-9027 (damoctocog alfa pegol); prophylactic treatment twice weekly, every 5 days or every 7 days for ≥50 exposure days.
Trial: 33725199
Drug: Current and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current and emerging therapies for cardiac amyloidosis
Trial: 33725322
Drug: Ropeginterferon alfa-2b
RxNorm normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ropeginterferon alfa-2b (100, 200, 300 µg)
Trial: 33725322
Drug: Ropeginterferon alfa-2b
RxNorm normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ropeginterferon alfa-2b (up to 300 µg)
Trial: 33726819
Drug: Positive end
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive end expiratory pressure titration
Trial: 33727862
Drug: Sensitive and
RxNorm normalized name: Nivea Sensitive and Radiant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensitive and highly sensitive responders to warfarin
Trial: 33727862
Drug: Normal responders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal responders to warfarin
Trial: 33727901
Drug: sacubitril-valsartan (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily)
Trial: 33727901
Drug: valsartan (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan (target dose, 160 mg twice daily)
Trial: 33728434
Drug: Nonadjuvanted seasonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadjuvanted seasonal influenza vaccine
Trial: 33728588
Drug: Oral HMAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HMAs
Trial: 33728588
Drug: Inhibitors of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors of splicing, CD123/dendritic cell axis, GM-CSF progenitor cell hypersensitivity, JAK/STAT pathway targeting
Trial: 33729718
Drug: Checklist for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Checklist for Early Recognition and Treatment of Acute Illness and Injury implementation
Trial: 33730360
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies (daratumumab, isatuximab, elotuzumab)
Trial: 33730360
Drug: Anti-BCMA antibody-drug
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-BCMA antibody-drug conjugate (belantamab mafodotin)
Trial: 33730360
Drug: Novel targets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel targets and constructs (bispecific antibodies against BCMA, GPRC5D, FCRH5)
Trial: 33730360
Drug: Antibody-based therapy
RxNorm normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody-based therapy
Trial: 33730841
Drug: Bruton's tyrosine
RxNorm normalized name: Bruton's tyrosine kinase (BTK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bruton's tyrosine kinase inhibitors
Trial: 33730841
Drug: Independent prognostic
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independent prognostic impact of treatment, β2-microglobulin and del(17p)
Trial: 33730841
Drug: Independent prognostic
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independent prognostic impact of treatment, del(11q), del(17p) and SF3B1 mutation
Trial: 33730844
Drug: Acalabrutinib 100
RxNorm normalized name: acalabrutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 100 mg twice daily until disease progression or intolerance
Trial: 33731219
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PAP and mindfulness
Trial: 33732892
Drug: μ-opioid agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: μ-opioid agonist buprenorphine
Trial: 33732892
Drug: μ-opioid antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: μ-opioid antagonist naltrexone
Trial: 33732892
Drug: inert pill
RxNorm normalized name: inert ingredients Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inert pill
Trial: 33733443
Drug: Stand-alone Xen45
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stand-alone Xen45 gel stent implantation
Trial: 33733980
Drug: Netarsudil ophthalmic
RxNorm normalized name: netarsudil ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netarsudil ophthalmic solution 0.02% prescribed once daily
Trial: 33733980
Drug: Netarsudil as
RxNorm normalized name: NETARSUDIL
DrugBank: Netarsudil (DB13931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Netarsudil as monotherapy
Trial: 33733980
Drug: Netarsudil as
RxNorm normalized name: NETARSUDIL
DrugBank: Netarsudil (DB13931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Netarsudil as concomitant therapy
Trial: 33734088
Drug: C-IPU (clinic-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-IPU (clinic-based multidisciplinary therapy)
Trial: 33734088
Drug: O-IPU (online
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-IPU (online integrated multidisciplinary therapy)
Trial: 33734415
Drug: cRGDY-PEG-Cy5.5-nanoparticles (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cRGDY-PEG-Cy5.5-nanoparticles (2 nmol, 0.4 mL)
Trial: 33734451
Drug: Remote delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote delivery of family-based therapy
Trial: 33735176
Drug: Sickle cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sickle cell disease (SCD) patients receiving specific treatment
Trial: 33735389
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (200 mg testosterone cypionate injected intramuscularly every 2 weeks for 18 months)
Trial: 33737338
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of OAd-MSCs plus G-CSF
Trial: 33737646
Drug: Infrequent iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrequent iron supplement treatment
Trial: 33737646
Drug: Hb 10.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hb 10.6 g/dL cutoff
Trial: 33737935
Drug: Intravenous rhC1-INH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rhC1-INH 50 U/kg (maximum, 4,200 U)
Trial: 33737935
Drug: Pre-treatment phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment phase (no rhC1-INH)
Trial: 33737954
Drug: Daclizumab beta
RxNorm normalized name: Daclizumab beta
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab beta 150 mg subcutaneously every 4 weeks for up to 5 years
Trial: 33738491
Drug: Adjuvant Ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Ozone Therapy
Trial: 33738668
Drug: Vorolanib (X-82),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, combined with everolimus.
Trial: 33738668
Drug: Everolimus (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (doses >5 mg).
Trial: 33739292
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence program lasting 6 months
Trial: 33739292
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence program lasting 12 months
Trial: 33739292
Drug: Electronic monitors
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic monitors and pill counts for assessing medication adherence
Trial: 33739857
Drug: Glofitamab (0.005-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glofitamab (0.005-30 mg)